Back to Search
Start Over
Gut microbiota diversity after autologous fecal microbiota transfer in acute myeloid leukemia patients
- Source :
- Nature Communications, Vol 12, Iss 1, Pp 1-11 (2021), Nature Communications, Nature Communications, Nature Publishing Group, 2021, 12 (1), pp.3084. ⟨10.1038/s41467-021-23376-6⟩, Nature Communications, 2021, 12 (1), pp.3084. ⟨10.1038/s41467-021-23376-6⟩
- Publication Year :
- 2021
- Publisher :
- Nature Portfolio, 2021.
-
Abstract
- Acute myeloid leukemia (AML) intensive chemotherapy combined with broad-spectrum antibiotics, leads to gut microbiota dysbiosis promoting pathological conditions and an increased incidence of complications. Here we report findings from a phase II single-arm, multicenter study evaluating autologous fecal microbiota transfer (AFMT) in 25 AML patients treated with intensive chemotherapy and antibiotics (ClinicalTrials.gov number: NCT02928523). The co-primary outcomes of the study are to evaluate the efficacy of AFMT in dysbiosis correction and multidrug-resistant bacteria eradication. The main secondary outcomes are to define a dysbiosis biosignature, to evaluate the effect of dysbiosis correction on patient clinical status, to assess the short and mid-term safety of AFMT in this immunocompromised population, and to evaluate the feasibility of the AFMT procedure and acceptability by the patient. Intensive induction chemotherapy induces a dramatic decrease of α-diversity indices, and a microbial dysbiosis with a significant shift of the microbial communities and domination of pro-inflammatory families. After AFMT treatment, α-diversity indices return to their initial mean levels and the similarity index shows the restoration of microbial communities. The trial meets pre-specified endpoints. AFMT appears to be safe and may be effective for gut microbiota restoration in AML patients receiving intensive chemotherapy and antibiotics, with an excellent gut microbiota reconstruction based on both richness and diversity indices at the species level.<br />The combination of chemotherapy and broad-spectrum antibiotics induces gut microbiota (GM) dysbiosis in acute myeloid leukaemia (AML) leading to additional complications. Here, the authors report the efficacy in GM restoration and safety of autologous faecal microbiota transfer in treated AML patients in a phase II clinical trial.
- Subjects :
- Male
0301 basic medicine
[SDV]Life Sciences [q-bio]
Antibiotics
General Physics and Astronomy
Gut flora
Feces
0302 clinical medicine
fluids and secretions
hemic and lymphatic diseases
Antineoplastic Combined Chemotherapy Protocols
Prospective Studies
education.field_of_study
Multidisciplinary
biology
Myeloid leukemia
Fecal Microbiota Transplantation
Middle Aged
Anti-Bacterial Agents
3. Good health
Leukemia
Treatment Outcome
Leukemia, Myeloid
030220 oncology & carcinogenesis
Acute Disease
Female
Adult
medicine.drug_class
Science
Population
Transplantation, Autologous
digestive system
Article
Phase II trials
Acute myeloid leukaemia
General Biochemistry, Genetics and Molecular Biology
Young Adult
03 medical and health sciences
medicine
Humans
education
Aged
Bacteria
business.industry
Induction chemotherapy
General Chemistry
biology.organism_classification
medicine.disease
Gastrointestinal Microbiome
Transplantation
030104 developmental biology
Immunology
Dysbiosis
business
Subjects
Details
- Language :
- English
- ISSN :
- 20411723 and 02928523
- Volume :
- 12
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- Nature Communications
- Accession number :
- edsair.doi.dedup.....d212c6f568912788089fd357a5492937